Endocrinology Advisor

Faricimab Upholds, Improves Visual Acuity With Fewer Injections in DME

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...
PharmiWeb

Ophthalmology Drugs Market Analysis by Key Drivers, Top Players, Forecast, Growth Rate, Constraints, Future Trends, Events, And Challenges Until 2030

Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...
Center for Biosimilars

Biosimilar QL1207 Demonstrates Equivalent Efficacy and Safety in DME

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Kodiak Sciences: Retinal Specialist Highlights Its Top Three Programs

Discover Kodiak's focused pipeline and late-stage trials advancing retinal disease therapies. Learn why KOD stands out in ...
Ophthalmology Times

Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positiveSOL-1 topline data ...
Center for Biosimilars

Swiss Analysis Shows Biosimilars Cut Costs but Longer-Interval Options Lead Savings

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
Ophthalmology Advisor

Anti-VEGF Reduces Myopia Odds in ROP, But Comes With Higher Risks

Anti-VEGF therapy for patients with retinopathy of prematurity reduces myopia compared with laser treatments, but comes with other risks.